GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 262
- Registration Number
- NCT00137969
- Locations
- 🇺🇸
Univ of Calif., Los Angeles; Rheumatology, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Emory Uni ; Division of Rheumatology, Atlanta, Georgia, United States
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 636
- Registration Number
- NCT00130728
- Locations
- 🇺🇸
Kaiser Permanente - Vallejo, Vallejo, California, United States
🇺🇸Anne Arundel Health System Research Instit-Annapolis Oncology Ctr, Annapolis, Maryland, United States
🇺🇸University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States
A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer
Phase 4
Terminated
- Conditions
- First Posted Date
- 2005-06-21
- Last Posted Date
- 2006-05-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 800
- Registration Number
- NCT00114946
A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-04-27
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 686
- Registration Number
- NCT00109317
A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-04-26
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00109252
A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-04-26
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00109200
An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-04-26
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00109187
A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-04-26
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00109239
A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-04-26
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00109226
A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-04-26
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00109265
© Copyright 2024. All Rights Reserved by MedPath